The FDA's 2026 decision lets people starting Leqembi for early Alzheimer's begin treatment with a once-weekly at-home injection instead of a biweekly infusion clinic visit. The agency approved Leqembi Iqlik (lecanemab-irmb) as an at-home subcutaneous starting dose on July 13-14, 2026, ahead of its extended review deadline, and Eisai and Biogen made the autoinjector available through specialty pharmacy on August 24, 2026.
The choice between the two routes does not change who qualifies for the drug, how closely the brain has to be monitored, or how long treatment lasts. It changes where the dose is given and who gives it. This checklist walks through what has to be lined up before a patient or caregiver switches to, or starts on, the at-home version.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Biospace — Use this primary source to verify the official announcement.
- Read the official guidance from Pharmexec — Use this primary source to verify the official guidance.
Table of Contents
- What the 2026 approval actually added
- At-home starting dose vs. IV infusion — the practical differences
- Does switching routes change the safety monitoring?
- Who administers the injection, and when
- A preparation checklist before the first dose
- Frequently Asked Questions
What the 2026 approval actually added
Leqembi already had a subcutaneous option before this decision. The FDA approved a subcutaneous autoinjector for maintenance-phase dosing — the lower, less frequent dose given after the initial treatment period — in late August 2025. That left the more intensive starting phase tied to IV infusions for another year. The 2026 decision closes that gap by approving the same autoinjector for the starting dose, not just maintenance.
That means a patient can now begin lecanemab treatment entirely at home, skip the infusion chair from day one, and stay on subcutaneous dosing straight through to maintenance if they choose. The approved population has not widened alongside the new delivery option. It still covers only adults with mild cognitive impairment or mild dementia caused by Alzheimer's disease — early-stage disease, the same indication the original IV label carried. A later-stage diagnosis does not become eligible just because the injection method changed.
At-home starting dose vs. IV infusion — the practical differences
The at-home starting dose is 500 mg given weekly, split into two 250 mg subcutaneous injections that each take about 15 seconds. After 18 months of treatment on either route, patients can move to a 360 mg once-weekly subcutaneous maintenance injection, and the label allows alternating between IV and subcutaneous dosing during treatment, so switching routes later does not lock a patient out of either option (Pharmaceutical Executive / Biogen). The IV alternative runs on a different schedule: an infusion lasting roughly one hour, given every two weeks during the initial phase in a clinical setting, with the patient observed during that first infusion. Non-U.S.
labeling is explicit that lecanemab must never be given as a rapid push or bolus — it has to be delivered as a timed infusion (TGA Australia product information). The time commitment is the clearest practical trade-off. IV infusions mean a biweekly trip to an infusion center and roughly an hour in the chair each time. The at-home injections take about 30 seconds total per week but can be self-administered or given by a caregiver once training is complete, according to Epocrates. Neither route is faster to show benefit — the dosing frequency and total drug exposure are what the FDA calibrated, not the delivery method.
Does switching routes change the safety monitoring?
No. Brain MRI monitoring for ARIA (amyloid-related imaging abnormalities, a type of swelling or bleeding the drug can trigger) is required before starting treatment and at specified intervals afterward, and that schedule is identical whether the drug is given by IV or by subcutaneous injection (Biogen/Eisai, summarized by trade press). Moving treatment home removes the infusion-center visit, not the MRI visits.
ApoE ε4 genotype — a gene variant linked to higher ARIA risk — matters regardless of route. People who carry two copies of the ε4 allele face a higher risk of ARIA, and the EU product label recommends ApoE ε4 testing before starting lecanemab specifically to inform that risk; Australia's label goes further and restricts approved use to non-carriers or single-copy carriers (EMA product information). Anyone considering either delivery method should expect this testing to come up before the first dose, not after.
Who administers the injection, and when
A health care provider is expected to guide at least the first at-home doses before a patient or caregiver moves to unsupervised self-administration, according to guidance the Alzheimer's Association has given on the autoinjector (Epocrates). This means the first weeks of at-home treatment still involve direct oversight, even though the eventual goal is a 15-second injection done without a clinic visit.
Caregivers taking on this role should expect manufacturer-run injection training and enrollment through a specialty pharmacy before the autoinjector reaches the home, since the drug is distributed through that channel rather than a regular retail pharmacy (Biogen investor release). Building in time for that enrollment step, rather than assuming same-week availability, avoids a gap between a diagnosis-confirmed decision to start treatment and the first dose actually arriving.
A preparation checklist before the first dose
Pulling the pieces above together, a patient or caregiver preparing to start or switch to at-home dosing should work through the same list regardless of which route they ultimately choose: None of these steps can be skipped by choosing the at-home option over IV, or vice versa — they sit upstream of the delivery method itself (synthesized from the sourced items above).
- Confirm the diagnosis is early-stage Alzheimer's disease — mild cognitive impairment or mild dementia — since that is the limit of the approved population.
- Ask about ApoE ε4 testing before the first dose, so ARIA risk is understood going in rather than discovered after symptoms appear.
- Schedule the required baseline MRI and the follow-up scans on the specified intervals; this monitoring schedule is the same for IV and at-home treatment.
- Complete manufacturer injection training and specialty-pharmacy enrollment ahead of when the first dose is needed, since the autoinjector ships through that channel rather than a standard pharmacy.
- Arrange for a health care provider to supervise the first at-home doses before shifting to unsupervised self- or caregiver-administration.
Frequently Asked Questions
Can a patient switch from IV infusions to the at-home injection partway through treatment?
Yes. The label allows alternating between IV and subcutaneous dosing during treatment, so a patient is not locked into the route they started on.
Does the at-home version reduce how often a patient needs an MRI?
No. The ARIA monitoring schedule before and during treatment is the same whether the drug is given by IV or subcutaneous injection.
Is the at-home injection approved for later-stage Alzheimer's disease?
No. The approved population is limited to mild cognitive impairment or mild dementia due to Alzheimer's disease, the same early-stage limit as the original IV approval.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: A Preparation Checklist for People With Early Alzheimer’s
- AAIC 2026 LatAm-FINGERS Cognitive Health Results: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: Data Questions Family Caregivers Should Ask
